Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 999 of 5804
-
Could a vaccine tame this rare brain disease?
Disease control Not yet recruitingThe Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP. Regimen A will evaluate the safety and efficacy of a single study drug, AADva…
Phase: PHASE2 • Sponsor: Adam Boxer • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat breast cancer
Disease control Recruiting nowThis phase II trial investigates how well 177Lu-DOTATATE works in treating patients with breast cancer that is stage IV or has come back (recurrent). 177Lu-DOTATATE may shrink or destroy the tumor or circulating breast cancer stem cells if they show evidence of the SSTR2. 177Lu-D…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for PSP: experimental drug LM11A-31 enters key trial
Disease control Not yet recruitingThe Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP. Regimen B will evaluate the safety and efficacy of a single study drug, LM11A-…
Phase: PHASE2 • Sponsor: Adam Boxer • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Triple therapy tackles tough lung cancer
Disease control TerminatedThis is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).
Phase: PHASE1 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug aims to slow kidney damage in rare alport syndrome
Disease control Recruiting nowThis is a randomized, double-Blind, placebo-controlled study to evaluate the efficacy and safety of exaluren in Alport Syndrome patients with nonsense mutations in COL4A3/4/5 genes. Targeted 24 patients aged 12 and older will be enrolled in the trial. The study will be comprise…
Phase: PHASE2 • Sponsor: Eloxx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New pacing technique could improve heart function in AF and heart failure patients
Disease control Not yet recruitingThis is a prospective, multicenter, randomized controlled trial comparing Left Bundle Branch Area Pacing (LBBAP)-based cardiac resynchronization therapy (CRT) with conventional coronary sinus (CS) lead-based CRT in patients with permanent atrial fibrillation (AF) and heart failur…
Phase: NA • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Can brain scans predict suicide risk in teens? new study aims to find out
Knowledge-focused Not yet recruitingThis study, titled "Neural Correlates of Suicidal Behavior in Youth: a Pre and Post CAMS Therapy Neuroimaging Study," aims to better understand the brain mechanisms underlying suicidal thoughts and behaviors in adolescents and young adults (ages 14-24). Suicide is a leading cause…
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
New drug SKB571 aims to shrink GI tumors in early trial
Disease control Not yet recruitingThis is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 in participants with gastrointestinal tumors.
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Electric shocks boost drug to shrink blood vessel tangles
Disease control Not yet recruitingIn biomedical applications, electroporation is used not only for cancer treatment but also for vaccinations, treatment of cardiac arrhythmias and, more recently, for the treatment of vascular malformations. Bleomycin is a frequently used sclerosing agent in the treatment of vario…
Phase: PHASE2 • Sponsor: Institute of Oncology Ljubljana • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New study tracks Real-World success of breast cancer drug in GCC
Knowledge-focused Not yet recruitingBEYOND study is designed to generate the first real-world data from GCC countries on the patient characteristics, treatment patterns, survival outcomes, and safety of T-DXd in patients with HRpositive,HER2-low or HER2-ultralow mBC previously treated with ET. The evidence generate…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New dosing strategy could mean fewer eye injections for Diabetes-Related vision loss
Disease control Not yet recruitingThe goal of this clinical trial is to understand whether Zhuochuming® (Aflibercept Intravitreal Injection) using a 3 loading doses followed by a treat-and-extend regimen (3+T\&E) can treat patients with diabetic macular edema (DME) who have not received prior treatment. It will a…
Phase: PHASE4 • Sponsor: The Third Peoples Hospital of Dalian • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for rare gut tumors? phase 2 trial launches
Disease control Not yet recruitingA phase 2 Study Evaluating the Efficacy and Safety of Single Agent AUR103 Calcium in Patients with Advanced, Well or Moderately differentiated Neuroendocrine Tumours. This is a Proof of Concept (PoC) Phase 2 study of AUR103 calcium in patients with advanced, well or moderately d…
Phase: PHASE2 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New dosing options for xywav could help fight daytime sleepiness
Symptom relief Not yet recruitingThe purpose of this study is to evaluate the efficacy and safety of expanded Xywav dosing regimens in adult participants with narcolepsy or idiopathic hypersomnia (IH).
Phase: PHASE3 • Sponsor: Jazz Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Glow-in-the-Dark dye could save voices in thyroid surgery
Symptom relief Not yet recruitingBevonescein (ALM-488) is a novel fluorescein-containing peptide that is intended as a visualization adjunct for the real-time enhanced structural delineation of major nerves during Head and Neck surgery to potentially improve patient outcomes.
Phase: PHASE2 • Sponsor: Matthew Spector • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New drug cocktail aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingFor Safety introduction phase,this study is to evaluate the safety and tolerability of LM-168 in combination with other anti-tumor treatment regimens in participants of advanced solid tumor trials, determine the maximum tolerated dose (MTD), and explore the recommended phase II d…
Phase: PHASE2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Strength training and protein diet may reverse frailty in sarcopenic elderly women
Disease control Recruiting nowSixty obese elderly women will be recruited from Fawkia hospital outpatient clinic diagnosed by sarcopenia and randomly allocated into two groups for a 12-week intervention. Patients will be divided into 2 groups (A and B): * Group A (combined intervention group: n=30): will per…
Phase: NA • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New oral drug aims to cut dangerous COPD exacerbations
Disease control Recruiting nowThis is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.
Phase: PHASE2 • Sponsor: Expedition Therapeutics, Inc • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Wearable sensors give Real-Time feedback to improve gait in children with hemiplegia
Disease control Not yet recruitingThe goal of this clinical trial is to learn about the effect of biofeedback-based inertial sensors gait training on walking parameters in children with hemiplegia. The main question it aims to answer is: Does biofeedback-based inertial sensors gait training have an effect on wal…
Phase: NA • Sponsor: Cairo University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
AI coach for parents of autistic kids: could a virtual simulation improve Real-Life communication?
Symptom relief Not yet recruitingThis randomized controlled trial evaluates an AI-based parental simulation designed to support reflective parenting, emotional regulation, and parent-child communication among parents of autistic children aged 3 to 12 years. A total of 140 parents will be recruited through an ext…
Phase: NA • Sponsor: University of Haifa • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
Old malaria drug may tame lupus skin flares
Disease control Not yet recruitingThe research study is being conducted to learn more about how patients with cutaneous lupus erythematosus (CLE) respond to the use of quinacrine. Quinacrine is a medication that was originally developed and used starting in the 1930's to treat malaria. It has been used for decade…
Phase: PHASE2 • Sponsor: Victoria Werth • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC